Ocular Therapeutix OCUL Amortization expense related to capitalized debt issuance costs
Amortization expense related to capitalized debt issuance costs at other companies
Other financials
Where this comes from
Reported directly by Ocular Therapeutix in its filing.
Tagged under the XBRL concept us-gaap:AmortizationOfFinancingCosts.
The official record: Ocular Therapeutix’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Ocular Therapeutix's amortization expense related to capitalized debt issuance costs.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Ocular Therapeutix's amortization expense related to capitalized debt issuance costs?
- Ocular Therapeutix (OCUL) reported amortization expense related to capitalized debt issuance costs of $1.38M in Q1 2026.
- How has Ocular Therapeutix's amortization expense related to capitalized debt issuance costs changed year-over-year?
- Ocular Therapeutix's amortization expense related to capitalized debt issuance costs decreased by 3.8% year-over-year, from $1.44M to $1.38M.
- What is the long-term trend for Ocular Therapeutix's amortization expense related to capitalized debt issuance costs?
- Over 4 years (2021 to 2025), Ocular Therapeutix's amortization expense related to capitalized debt issuance costs has grown at a -7.4% compound annual growth rate (CAGR), from $4.63M to $3.4M.